GlobeStar Therapeutics Corporation

Equities

GSTC

US37960P1049

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 09:47:17 2024-07-05 EDT			5-day change	1st Jan Change
0.0006 ^USD	-25.00%		-40.00%	-33.33%

06-28	GlobeStar Therapeutics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
03-12	GlobeStar Therapeutics Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

GlobeStar Therapeutics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024

June 28, 2024 at 05:08 pm

GlobeStar Therapeutics Corporation reported earnings results for the second quarter and six months ended March 31, 2024. For the second quarter, the company reported net loss was USD 0.174962 million compared to USD 0.150237 million a year ago.
For the six months, net loss was USD 0.338721 million compared to USD 0.316146 million a year ago.

Latest news about GlobeStar Therapeutics Corporation

GlobeStar Therapeutics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	06-28	CI
GlobeStar Therapeutics Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	03-12	CI
Globestar Therapeutics Corporation Reports Earnings Results for the Third Quarter Ended June 30, 2021	21-08-23	CI

Chart GlobeStar Therapeutics Corporation

Duration

Period

Chart GlobeStar Therapeutics Corporation

More charts

Company Profile

GlobeStar Therapeutics Corporation (GlobeStar Therapeutics) is a clinical-stage pharmaceutical company. The Company is focused on introducing a patented formulation of drugs for the treatment of Multiple Sclerosis and other neurodegenerative diseases. The Company owns the global license from the inventors, who are based in Italy. The Company has acquired a license for a patented method of treating neurodegenerative diseases such as Multiple Sclerosis by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration and treating neurodegeneration. GlobeStar Therapeutics is initiating discussions with the Food and Drug Administration (FDA) on clinical trial design in preparation for FDA submission and approval pathway.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GLOBESTAR THERAPEUTICS CORPORATION	-33.33%	993K
MODERNA, INC.	+16.60%	44.44B
LONZA GROUP AG	+42.04%	40.03B
IQVIA HOLDINGS INC.	-11.03%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+29.84%	31.46B
CELLTRION, INC.	-9.23%	27.29B
ICON PUBLIC LIMITED COMPANY	+12.29%	26.29B
UNITED THERAPEUTICS CORPORATION	+42.61%	13.8B
MEDPACE HOLDINGS, INC.	+30.25%	12.46B
BIO-TECHNE CORPORATION	-7.83%	11.26B

Other Biotechnology & Medical Research